Literature DB >> 27984531

Reply.

Jennifer S Gewandter1, Robert H Dworkin1, Nanna B Finnerup2, Roy Freeman3, Nimish A Mohile4.   

Abstract

Entities:  

Year:  2017        PMID： 27984531      PMCID： PMC7251773          DOI： 10.1097/j.pain.0000000000000744

Source DB:  PubMed          Journal:  Pain        ISSN： 0304-3959            Impact factor:   7.926


× No keyword cloud information.
  9 in total

Review 1.  Chemotherapy-Induced Peripheral Neurotoxicity assessment: a critical revision of the currently available tools.

Authors:  Guido Cavaletti; Barbara Frigeni; Francesca Lanzani; Laura Mattavelli; Emanuela Susani; Paola Alberti; Diego Cortinovis; Paolo Bidoli
Journal:  Eur J Cancer       Date:  2010-01-04       Impact factor: 9.162

Review 2.  Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis.

Authors:  Marta Seretny; Gillian L Currie; Emily S Sena; Sabrina Ramnarine; Robin Grant; Malcolm R MacLeod; Leslie A Colvin; Marie Fallon
Journal:  Pain       Date:  2014-09-23       Impact factor: 6.961

3.  Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial.

Authors:  Ellen M Lavoie Smith; Herbert Pang; Constance Cirrincione; Stewart Fleishman; Electra D Paskett; Tim Ahles; Linda R Bressler; Camilo E Fadul; Chetaye Knox; Nguyet Le-Lindqwister; Paul B Gilman; Charles L Shapiro
Journal:  JAMA       Date:  2013-04-03       Impact factor: 56.272

Review 4.  Measures of chemotherapy-induced peripheral neuropathy: a systematic review of psychometric properties.

Authors:  Kathleen A Griffith; Ingemar S J Merkies; Elizabeth E Hill; David R Cornblath
Journal:  J Peripher Nerv Syst       Date:  2010-12       Impact factor: 3.494

Review 5.  Content validity of symptom-based measures for diabetic, chemotherapy, and HIV peripheral neuropathy.

Authors:  Jennifer S Gewandter; Laurie Burke; Guido Cavaletti; Robert H Dworkin; Christopher Gibbons; Tony D Gover; David N Herrmann; Justin C Mcarthur; Michael P McDermott; Bob A Rappaport; Bryce B Reeve; James W Russell; A Gordon Smith; Shannon M Smith; Dennis C Turk; Aaron I Vinik; Roy Freeman
Journal:  Muscle Nerve       Date:  2016-12-23       Impact factor: 3.217

6.  Thermal hyperalgesia as a marker of oxaliplatin neurotoxicity: a prospective quantified sensory assessment study.

Authors:  N Attal; D Bouhassira; M Gautron; J N Vaillant; E Mitry; C Lepère; P Rougier; F Guirimand
Journal:  Pain       Date:  2009-05-19       Impact factor: 6.961

7.  The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings.

Authors:  G Cavaletti; D R Cornblath; I S J Merkies; T J Postma; E Rossi; B Frigeni; P Alberti; J Bruna; R Velasco; A A Argyriou; H P Kalofonos; D Psimaras; D Ricard; A Pace; E Galiè; C Briani; C Dalla Torre; C G Faber; R I Lalisang; W Boogerd; D Brandsma; S Koeppen; J Hense; D Storey; S Kerrigan; A Schenone; S Fabbri; M G Valsecchi; A Mazzeo; A Pace; A Pessino; A Schenone; A Toscano; A A Argyriou; B Brouwer; B Frigeni; B Piras; C Briani; C Dalla Torre; C Dominguez Gonzalez; C G Faber; C Tomasello; D Binda; D Brandsma; D Cortinovis; D Psimaras; D Ricard; D Storey; D R Cornblath; E Galiè; E Lindeck Pozza; E Rossi; E K Vanhoutte; F Lanzani; F Pastorelli; G Altavilla; G Cavaletti; G Granata; H P Kalofonos; I Ghignotti; I S J Merkies; J Bruna; J Hense; J J Heimans; L Mattavelli; L Padua; L Reni; M Bakkers; M Boogerd; M Campagnolo; M Cazzaniga; M Eurelings; M Leandri; M Lucchetta; M Penas Prado; M Russo; M G Valsecchi; M L Piatti; P Alberti; P Bidoli; R Grant; R Plasmati; R Velasco; R I Lalisang; R J Meijer; S Fabbri; S G Dorsey; S Galimberti; S Kerrigan; S Koeppen; T J Postma; W Boogerd; W Grisold
Journal:  Ann Oncol       Date:  2012-08-21       Impact factor: 32.976

8.  Chemotherapy-induced pain and neuropathy: a prospective study in patients treated with adjuvant oxaliplatin or docetaxel.

Authors:  Lise Ventzel; Anders B Jensen; Anni R Jensen; Troels S Jensen; Nanna B Finnerup
Journal:  Pain       Date:  2016-03       Impact factor: 6.961

Review 9.  Research design considerations for chronic pain prevention clinical trials: IMMPACT recommendations.

Authors:  Jennifer S Gewandter; Robert H Dworkin; Dennis C Turk; John T Farrar; Roger B Fillingim; Ian Gilron; John D Markman; Anne Louise Oaklander; Michael J Polydefkis; Srinivasa N Raja; James P Robinson; Clifford J Woolf; Dan Ziegler; Michael A Ashburn; Laurie B Burke; Penney Cowan; Steven Z George; Veeraindar Goli; Ole X Graff; Smriti Iyengar; Gary W Jay; Joel Katz; Henrik Kehlet; Rachel A Kitt; Ernest A Kopecky; Richard Malamut; Michael P McDermott; Pamela Palmer; Bob A Rappaport; Christine Rauschkolb; Ilona Steigerwald; Jeffrey Tobias; Gary A Walco
Journal:  Pain       Date:  2015-07       Impact factor: 7.926
  9 in total
  1 in total

1.  A Multimodal Approach to Discover Biomarkers for Taxane-Induced Peripheral Neuropathy (TIPN): A Study Protocol.

Authors:  Anukriti Sharma; Ken B Johnson; Bihua Bie; Emily E Rhoades; Alper Sen; Yuri Kida; Jennifer Hockings; Alycia Gatta; Jacqueline Davenport; Connie Arcangelini; Jennifer Ritzu; Jennifer DeVecchio; Ron Hughen; Mei Wei; G Thomas Budd; N Lynn Henry; Charis Eng; Joseph Foss; Daniel M Rotroff
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.